In focus
Latest feed
Bio-Techne: Navigating Choppy Waters – Is a Recovery Enough for a Valuation Boost?
CureVac's Crossroads: Why Wall Street Is Treading Carefully Towards 2026
The Shifting Sands of Commerce: A Week of Bold Plays and Strategic Pivots
The $8.9 Billion Bet: Thermo Fisher's Bold Play to Redefine Clinical Trials
